Isarna Therapeutics GmbH

Isarna Therapeutics GmbH is a biotechnology startup based in Germany. With the slogan "Developing first in class antisense therapies for blockbuster retina indications," Isarna focuses on developing ISTH0036, a next-generation antisense to block TGF-beta 2 production, aiming to revolutionize retinal disease therapy. The company's leadership, including COO Rene Rückert, MD, MBA and CMO Prof. Marion Munk, MD, PhD, brings significant industry expertise, having led the global development of approved blockbuster drugs for retinal diseases at Bayer/Novartis. Isarna's innovative approach targets the limitations of current therapies for retinal diseases by addressing the progression of the disease and fibrosis development. The Phase 1 study of ISTH0036 demonstrated excellent safety, paving the way for the company's preparation for a Phase 2a study in wet AMD and in DME/DR. The potential of ISTH0036 to be a long-term treatment in several retinal pathologies, including the blockbuster-indications wAMD, DME, and RVO, indicates a significant upward potential in dry AMD. Notably, $7.60M in Venture Round investment was secured on 24 April 2014, with funding from MIG AG and Global Asset Fund. As Isarna Therapeutics seeks to expand its clinical development and growth, the company is welcoming discussions for future partnerships and seeking investors to further finance its endeavors. With its promising therapy and esteemed leadership, Isarna is positioned as a compelling opportunity in the biotechnology and retinal disease treatment sectors.